Announced details
Healthcare, organ fibrosis, rare diseases and biopharmaceuticals
Gyre Pharmaceuticals is a major constituent company of our group. Rongzhong Research is a third-party institution that hosted and announced this list.
A research institution covering China’s venture capital/private equity market and new economy sectors. Location, representative, capital and year established: Not disclosed.
Rongzhong 2025-2026 China Future Unicorn Companies TOP 50
Rongzhong (Rongzhong Research)
The specific amount or percentage impact on performance resulting from this selection is Not disclosed. The disclosure states that it is expected to have a positive impact on areas including government support, partnership negotiations and talent acquisition.
The company does not address Contract Value / Offering price.
Rongzhong Research’s proprietary database, Bridge Data, together with surveys, expert interviews and multidimensional publicly available information.
| Item | Details |
|---|---|
| Names of Products / Services Covered | New drug research and development, manufacturing and commercialization business in organ fibrosis and rare diseases |
| Counterparty | Rongzhong (Rongzhong Research) |
| Counterparty overview | A research institution covering China’s venture capital/private equity market and new economy sectors. Location, representative, capital and year established: Not disclosed. |
| Relationship with the Company | Gyre Pharmaceuticals is a major constituent company of our group. Rongzhong Research is a third-party institution that hosted and announced this list. |
| Applicable area | Healthcare, organ fibrosis, rare diseases and biopharmaceuticals |
| Award/certification name | Rongzhong 2025-2026 China Future Unicorn Companies TOP 50 |
| Awarding / certifying body | Rongzhong (Rongzhong Research) |
| Impact on Business Performance | The specific amount or percentage impact on performance resulting from this selection is Not disclosed. The disclosure states that it is expected to have a positive impact on areas including government support, partnership negotiations and talent acquisition. |
| Source | Rongzhong Research’s proprietary database, Bridge Data, together with surveys, expert interviews and multidimensional publicly available information. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company was selected following an assessment by Rongzhong Research based on a range of indicators, including business scale, innovation, financial soundness and social recognition.